GSK's Linerixibat Gets UK Nod for Itch Linked to Biliary Disease
Igår, 16:13
10:13 AM EDT, 05/01/2026 (MT Newswires) -- GSK's (GSK) Linerixibat, to be marketed as Lynavoy, has been approved by the UK's Medicines and Healthcare products Regulatory Agency for the treatment of itching in adults with primary biliary cholangitis, the agency said Friday.
The oral therapy aims to reduce bile acid buildup linked to the rare liver disease, which can cause persistent itching, the agency said.
The approval was supported by phase 3 data showing Linerixibat significantly reduced itching and improved sleep disruption compared with placebo, it added.
Shares of GSK were down 1.2% in Friday trading.
Price: 52.01, Change: -0.30, Percent Change: -0.57
GSK's Linerixibat Gets UK Nod for Itch Linked to Biliary Disease
Igår, 16:13
10:13 AM EDT, 05/01/2026 (MT Newswires) -- GSK's (GSK) Linerixibat, to be marketed as Lynavoy, has been approved by the UK's Medicines and Healthcare products Regulatory Agency for the treatment of itching in adults with primary biliary cholangitis, the agency said Friday.
The oral therapy aims to reduce bile acid buildup linked to the rare liver disease, which can cause persistent itching, the agency said.
The approval was supported by phase 3 data showing Linerixibat significantly reduced itching and improved sleep disruption compared with placebo, it added.
Shares of GSK were down 1.2% in Friday trading.
Price: 52.01, Change: -0.30, Percent Change: -0.57
Analys
Rapporter
Analys
Rapporter
Marknadsöversikt
1 DAG %
Senast
1 mån
